Thalassemia-free survival after allogeneic stem cell transplantation (SCT) is about 80–90%
with either matched-related or-unrelated donors. We explored the use of a mismatched …

In haploidentical stem cell transplantations (haplo-SCT), nearly all patients have more than
one donor. A key issue in the haplo-SCT setting is the search for the best donor, because …

目的探讨单倍体与同胞相合异基因造血干细胞移植治疗恶性血液病疗效及影响预后的相关因素.
方法分析2013 年6 月—2019 年12 月于山西白求恩医院行异基因造血干细胞移植的82 …

Aplastic anemia (AA) is a serious hematological disorder, which is solely cured by
hematopoietic stem cell transplantation (HSCT). Haploidentical HSCT is an emerging …

AML is currently the first indication for allogeneic hematopoietic stem cell transplantation
(allo-HSCT), as shown by international transplant registries. The conditioning regimens are …

Hematopoietic cell transplantation (HCT) activity in China was surveyed to assess its current
status. A record number of HCTs (21 884: 16 631 allogeneic (76%) and 5253 autologous …

Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the treatment of
choice to consolidate remission in patients with poor-risk acute myeloid leukemia (AML) …

The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed
adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence …

Hematopoietic stem cell transplantation (HSCT) is a highly effective and unique medical
procedure for the treatment of most hematological malignancies. The first allogeneic …

Prior data indicate similar outcomes after transplants from human leukocyte antigen (HLA)-
haplotype-matched relatives, HLA-identical siblings and HLA-matched unrelated donors …